The non-small cell lung cancer diagnosis by thinprep cytology test and immunocytochemistry in sputum exfoliated cells

陈江帆; 李春英; 孙秀娟; 郑绍光

doi:10.3969/j.issn.1007-3969.2014.03.005

您当前的位置：

首页 >

文章列表页 >

The non-small cell lung cancer diagnosis by thinprep cytology test and immunocytochemistry in sputum exfoliated cells

更新时间：2025-12-31

- The non-small cell lung cancer diagnosis by thinprep cytology test and immunocytochemistry in sputum exfoliated cells
- China Oncology Vol. 24, Issue 3, Pages: 182-186(2014)
- 作者机构：
  
  柳州市柳铁中心医院病理科,广西,柳州,545007
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.03.005
  CLC：
- Published Online：01 April 2014，
  
  Published：01 April 2014
- 稿件说明：
移动端阅览
陈江帆,李春英,孙秀娟,郑绍光. 液基细胞学联合免疫细胞化学在痰液脱落细胞诊断非小细胞肺癌中的应用[J]. 中国癌症杂志, 2014, 24(3): 182-186.

陈江帆, 李春英, 孙秀娟, et al. The non-small cell lung cancer diagnosis by thinprep cytology test and immunocytochemistry in sputum exfoliated cells[J]. China Oncology, 2014, 24(3): 182-186.
陈江帆,李春英,孙秀娟,郑绍光. 液基细胞学联合免疫细胞化学在痰液脱落细胞诊断非小细胞肺癌中的应用[J]. 中国癌症杂志, 2014, 24(3): 182-186. DOI： 10.3969/j.issn.1007-3969.2014.03.005.

陈江帆, 李春英, 孙秀娟, et al. The non-small cell lung cancer diagnosis by thinprep cytology test and immunocytochemistry in sputum exfoliated cells[J]. China Oncology, 2014, 24(3): 182-186. DOI： 10.3969/j.issn.1007-3969.2014.03.005.

摘要

背景与目的：肺癌中非小细胞肺癌(non-small cell lung cancer，NSCLC)发病率最高，NSCLC痰液脱落细胞学诊断已成为肺癌早期诊断的重要辅助手段。本研究旨在探讨液基细胞学和免疫细胞化学方法在NSCLC恶性痰液脱落细胞学标本的分类与诊断中的应用价值。方法：应用液基薄层细胞学自动涂片技术方法筛查到可疑肿瘤细胞及肿瘤细胞的恶性痰液标本共530例进行细胞包埋连续切片，分别作NSCLC肿瘤细胞标志物细胞角蛋白7(cytokeratin-7，CK7)、细胞角蛋白5/6(cytokeratin-5/6，CK5/6)、甲状腺转录因子-1(thyroidtranscription factor-1，TTF-1)、P63、上皮膜抗原(epithelial membrane antigen，EMA)免疫细胞化学染色。结果：530例NSCLC恶性痰液患者确诊为肺腺癌265例，鳞癌246例，腺鳞癌19例。TTF-1和CK7在腺癌中有明显高表达，阳性表达率为92.45%(245/265)和91.70%(243/265)；CK5/6和P63在鳞癌中有明显高表达，阳性表达率为97.15%(239/246)和99.59%(245/246)。结论：液基细胞学与免疫细胞化学技术相结合在痰液标本诊断中有很重要的临床意义，CK7、CK5/6、TTF-1、P63、EMA联合可用于NSCLC恶性痰液的分类与诊断，值得在临床细胞病理学诊断中推广应用。

Abstract

Background and purpose: The non-small cell lung cancer (NSCLC) has been the highest disease incidence in lung cancer

sputum cytology diagnosis has become an important adjunct to the early diagnosis of lung cancer. The purpose of this study was to investigate the value of thinprep cytological and immunocytochemical method in differentiatial diagnosis of exfoliated cells of malignant sputum in NSCLC. Methods: Sputum samples were detected with thinprep cytology test

a total of 530 cases suspicious tumor cells and malignant tumor cells sputum specimens were randomly selected in continuous paraffin-embedded sections

respectively

NSCLC tumor cell markers CK7

CK5/6

TTF-1

P63

EMA were evaluted by immunocytochemical staining. Results: Of the 530 cases of malignant sputum

these were confirmed 265 cases of lung adenocarcinoma

246 cases of squamous carcinoma

19 cases of adeno-squamous carcinoma. Moreover

TTF-1 and CK7 were significantly higher expressed in adenocarcinoma

the positive rates were 92.45% (245/265) and 91.70% (243/265); CK5/6 and P63 were significantly higher expressed in squamous carcinoma

the positive rates were 97.15% (239/246) and 99.59% (245/246). Conclusion: Liquid-based cytology combined with immunocytochemistry had important clinical value in classification and identification of sputum samples

the combination of CK7

CK5/6

TTF-1

P63

EMA can be used for classification and identification of malignant sputum samples between NSCLC

is worthy of promoting in clinical cytopathology diagnosis.

关键词

Keywords

references

Views

3359

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Important clinical research progress in lung cancer in 2022

Research progress of ALK kinase domain drug resistance mutation and its future countermeasures

Related Author

Qiling DENG

Di SONG

Kexin XI

Xiaoting XIE

Xiaoyan WU

Wei ZHAO

Yicong LIN

Yue WANG

Related Institution

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Oncology, Peking University International Hospital

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

AI问答

⁰